Cooper Companies Inc (NYSE:COO) Expected to Announce Earnings of $2.79 Per Share

Wall Street brokerages expect Cooper Companies Inc (NYSE:COO) to post $2.79 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Cooper Companies’ earnings. The lowest EPS estimate is $2.70 and the highest is $3.07. Cooper Companies posted earnings per share of $2.88 in the same quarter last year, which would indicate a negative year-over-year growth rate of 3.1%. The company is scheduled to announce its next earnings results on Tuesday, March 3rd.

On average, analysts expect that Cooper Companies will report full-year earnings of $12.99 per share for the current financial year, with EPS estimates ranging from $12.76 to $13.26. For the next fiscal year, analysts anticipate that the company will post earnings of $14.37 per share, with EPS estimates ranging from $14.07 to $14.80. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover Cooper Companies.

Cooper Companies (NYSE:COO) last posted its earnings results on Thursday, December 5th. The medical device company reported $3.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.27 by $0.03. Cooper Companies had a net margin of 17.08% and a return on equity of 17.15%. The business had revenue of $691.60 million for the quarter, compared to analyst estimates of $683.83 million. During the same period in the prior year, the company posted $2.87 EPS. The company’s revenue for the quarter was up 6.2% on a year-over-year basis.

Several brokerages recently commented on COO. Raymond James dropped their price target on Cooper Companies from $364.00 to $355.00 and set an “in-line” rating for the company in a research report on Friday. Northcoast Research restated a “buy” rating on shares of Cooper Companies in a report on Tuesday. Zacks Investment Research raised Cooper Companies from a “sell” rating to a “hold” rating and set a $325.00 target price for the company in a research note on Wednesday, November 20th. Jefferies Financial Group reduced their price target on Cooper Companies from $358.00 to $330.00 and set an “in-line” rating on the stock in a report on Wednesday. Finally, KeyCorp boosted their price target on shares of Cooper Companies from $348.00 to $351.00 and gave the company an “overweight” rating in a research report on Wednesday, November 27th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and eight have issued a buy rating to the company’s stock. Cooper Companies presently has an average rating of “Buy” and an average target price of $324.83.

In related news, Director Allan E. Rubenstein sold 1,335 shares of the stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $299.61, for a total value of $399,979.35. Following the completion of the transaction, the director now directly owns 3,591 shares in the company, valued at $1,075,899.51. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.70% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Commonwealth Equity Services LLC boosted its stake in Cooper Companies by 1.8% during the second quarter. Commonwealth Equity Services LLC now owns 3,650 shares of the medical device company’s stock worth $1,229,000 after buying an additional 66 shares during the period. Flagship Harbor Advisors LLC increased its position in shares of Cooper Companies by 62.5% during the second quarter. Flagship Harbor Advisors LLC now owns 78 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 30 shares during the last quarter. Whittier Trust Co. acquired a new stake in shares of Cooper Companies during the second quarter valued at about $53,000. Commerzbank Aktiengesellschaft FI raised its stake in shares of Cooper Companies by 74.3% in the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 3,523 shares of the medical device company’s stock valued at $1,187,000 after acquiring an additional 1,502 shares during the period. Finally, Arden Trust Co purchased a new stake in shares of Cooper Companies in the 2nd quarter valued at approximately $205,000. Hedge funds and other institutional investors own 95.35% of the company’s stock.

NYSE:COO traded down $5.67 during trading hours on Monday, reaching $307.19. 741,150 shares of the company were exchanged, compared to its average volume of 321,306. The firm has a market cap of $15.47 billion, a PE ratio of 26.71, a price-to-earnings-growth ratio of 2.31 and a beta of 0.91. Cooper Companies has a twelve month low of $228.65 and a twelve month high of $344.32. The stock’s 50-day moving average is $298.29 and its 200-day moving average is $312.06. The company has a current ratio of 1.29, a quick ratio of 0.73 and a debt-to-equity ratio of 0.39.

About Cooper Companies

The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.

Featured Article: What does the Dow Jones Industrial Average (DJIA) measure?

Get a free copy of the Zacks research report on Cooper Companies (COO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cooper Companies (NYSE:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.